Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Home News ArchiveThe New York Times Company to Report Third-Quarter Results November 4, 2026

Live News EQUITY FLASH M impact Oct 14, 2026, 01:07 PM UTC

The New York Times Company to Report Third-Quarter Results November 4, 2026

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

NYT

Related stories

Eastern Province Cement Reports Q3 Profit of SAR 50 Million M impact | EQUITY | Oct 25, 2026, 12:50 PM UTC Arabian Cement Reports Q3 Profit of SAR 28 Million M impact | EQUITY | Oct 25, 2026, 12:50 PM UTC Bahri Orders Three VLCCs From IMI in 1.69 Billion Riyal Contract Saudi-listed Bahri placed orders for three very large crude carriers with International Maritime Industries. The order is valued at 1.69 billion Saudi riyals. M impact | EQUITY | Oct 25, 2026, 11:50 AM UTC Kelun-Biotech trial shows 31% lower death risk versus chemotherapy Final overall survival results from Phase III OptiTROP-Lung04 showed sac-TMT monotherapy cut the risk of death by 31% versus a platinum doublet in EGFR-mutant NSCLC after EGFR-TKI. M impact | EQUITY | Oct 25, 2026, 11:13 AM UTC Genmab Reports Phase 2 ORRs of 75% and 67% in mCRC Genmab reported updated results for petosemtamab plus FOLFOX/FOLFIRI, with ORRs of 75% in first-line and 67% in second-line patients. ORR was 81% in first-line left-sided tumors; t M impact | EQUITY | Oct 25, 2026, 11:04 AM UTC Kelun-Biotech Phase III Trial Shows PFS Improvement in NSCLC Kelun-Biotech said the OptiTROP-Lung06 trial met its primary endpoint, with sac-TMT plus pembrolizumab significantly improving progression-free survival versus platinum doublet plu M impact | EQUITY | Oct 25, 2026, 10:45 AM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Market Context
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.